Perspective Therapeutics, Inc.
CATX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000728387
In the last 90 days, Perspective Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Perspective Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 98
- −14 vs. Q1 2025
- Shares held
- 42.5M
- −2.79M (−6.2%) vs. Q1 2025
- Total value
- $146.3M
- +$49.9M (+51.8%) vs. Q1 2025
- New holders
- 10
- 40 more added
- Sold out
- 24
- 22 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CATX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $297.6M |
| Q1 2026 | 138 | $333.1M |
| Q4 2025 | 117 | $105.0M |
| Q3 2025 | 105 | $150.1M |
| Q2 2025 | 98 | $146.3M |
| Q1 2025 | 112 | $96.4M |
| Q4 2024 | 135 | $150.7M |
| Q3 2024 | 127 | $654.9M |
| Q2 2024 | 105 | $384.9M |
| Q1 2024 | 104 | $294.6M |
| Q4 2023 | 52 | $14.7M |
| Q3 2023 | 49 | $9.99M |
| Q2 2023 | 50 | $22.0M |
| Q1 2023 | 42 | $17.8M |
| Q4 2022 | 48 | $4.26M |
| Q3 2022 | 35 | $3.70M |
| Q2 2022 | 43 | $5.19M |
| Q1 2022 | 39 | $5.79M |
| Q4 2021 | 45 | $6.78M |
| Q3 2021 | 43 | $9.99M |
| Q2 2021 | 48 | $13.9M |
| Q1 2021 | 57 | $20.2M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Perspective Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −163,460−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −115,255−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −96,060−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −61,021−100.0% | Sold out |
| Virtus Investment Advisers, Inc. | 0 | $0 | 0.00% | −47,307−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −32,569−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −30,854−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −26,483−100.0% | Sold out |
| AMG National Trust Bank | 0 | $0 | 0.00% | −23,423−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −20,789−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −15,763−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −15,158−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −14,805−100.0% | Sold out |
| CIBC World Markets Corp | 0 | $0 | 0.00% | −11,995−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −10,770−100.0% | Sold out |
| Carolinas Wealth Consulting LLC | 0 | $0 | 0.00% | −1,097−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −895−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |